• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

耐 ADP-核糖基化利福布汀类似物对干酪素替代物中耐药结核分枝杆菌具有增强的杀菌活性。

ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant in caseum surrogate.

机构信息

Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey, USA.

Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota , Minneapolis, Minnesota, USA.

出版信息

Antimicrob Agents Chemother. 2023 Sep 19;67(9):e0038123. doi: 10.1128/aac.00381-23. Epub 2023 Jul 26.

DOI:10.1128/aac.00381-23
PMID:37493373
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10508146/
Abstract

Necrotic lesions and cavities filled with caseum are a hallmark of mycobacterial pulmonary disease. Bronchocavitary disease is associated with poor treatment outcomes. In caseum surrogate, entered an extended stationary phase showing tolerance to killing by most current antibiotics, suggesting that caseum persisters contribute to the poor performance of available treatments. Novel ADP-ribosylation-resistant rifabutin analogs exhibited bactericidal activity against these persisters at concentrations achievable by rifamycins in caseum.

摘要

干酪样坏死病变和充满干酪样物质的空洞是分枝杆菌肺病的一个标志。支气管空洞性疾病与治疗效果不佳有关。在干酪样物质替代物中,分枝杆菌进入延长的静止期,表现出对大多数现有抗生素的杀伤作用的耐受性,这表明干酪样物质的持续存在有助于现有治疗方法的疗效不佳。新型 ADP-ribosylation- resistant 利福布汀类似物在干酪样物质中可达到利福霉素浓度时对这些持续存在的分枝杆菌表现出杀菌活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28b0/10508146/6a2cbda7bdce/aac.00381-23.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28b0/10508146/80af0785e982/aac.00381-23.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28b0/10508146/6a2cbda7bdce/aac.00381-23.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28b0/10508146/80af0785e982/aac.00381-23.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28b0/10508146/6a2cbda7bdce/aac.00381-23.f002.jpg

相似文献

1
ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant in caseum surrogate.耐 ADP-核糖基化利福布汀类似物对干酪素替代物中耐药结核分枝杆菌具有增强的杀菌活性。
Antimicrob Agents Chemother. 2023 Sep 19;67(9):e0038123. doi: 10.1128/aac.00381-23. Epub 2023 Jul 26.
2
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.阻断细菌萘氢醌氧化和 ADP-核糖基化可提高利福霉素类药物对脓肿分枝杆菌的活性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0097821. doi: 10.1128/AAC.00978-21.
3
Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.利福布丁与一线抗分枝杆菌抗生素克拉霉素和替加环素协同作用并具有杀菌作用,提示这是一种有效的治疗组合。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00283-18. Print 2018 Aug.
4
Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.利福布汀对脓肿分枝杆菌的细胞内和细胞外形式均具有杀菌作用。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00363-20.
5
Rifabutin Is Active against Mycobacterium abscessus in Mice.利福布汀对小鼠中的脓肿分枝杆菌有效。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.
6
In vitro activity of rifabutin against Mycobacterium abscessus, clinical isolates.利福布汀对脓肿分枝杆菌临床分离株的体外活性。
Clin Exp Pharmacol Physiol. 2022 Jul;49(7):767-775. doi: 10.1111/1440-1681.13651. Epub 2022 Jun 5.
7
Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, , , and in BALB/c mice models.PBTZ169 和普托马尼德对 BALB/c 小鼠模型中鸟分枝杆菌、胞内分枝杆菌、堪萨斯分枝杆菌和偶发分枝杆菌的疗效。
Front Cell Infect Microbiol. 2023 Mar 22;13:1115530. doi: 10.3389/fcimb.2023.1115530. eCollection 2023.
8
Rifabutin Is Active against Mycobacterium abscessus Complex.利福布汀对脓肿分枝杆菌复合群有活性。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00155-17. Print 2017 Jun.
9
Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.阻断ADP-核糖基化可扩大利福霉素的抗分枝杆菌谱。
Microbiol Spectr. 2023 Sep 8;11(5):e0190023. doi: 10.1128/spectrum.01900-23.
10
Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Complex.利福布汀与克拉霉素、亚胺培南和替加环素联合应用对复合体的协同作用。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02234-18. Print 2019 Apr.

引用本文的文献

1
Activity of combinations of bactericidal and bacteriostatic compounds in -infected mice: an overview.感染小鼠中杀菌和抑菌化合物组合的活性:综述。
Front Microbiol. 2025 Aug 1;16:1616149. doi: 10.3389/fmicb.2025.1616149. eCollection 2025.
2
Next-generation rifamycins for the treatment of mycobacterial infections.用于治疗分枝杆菌感染的新一代利福霉素类药物。
Proc Natl Acad Sci U S A. 2025 May 6;122(18):e2423842122. doi: 10.1073/pnas.2423842122. Epub 2025 May 1.
3
Toward a Bactericidal Oral Drug Combination for the Treatment of Lung Disease.

本文引用的文献

1
A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.一种新型工具,可鉴定干酪样物中耐药物结核分枝杆菌的脆弱靶标中的杀菌化合物。
mBio. 2023 Apr 25;14(2):e0059823. doi: 10.1128/mbio.00598-23. Epub 2023 Apr 5.
2
Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.重新设计利福霉素抗生素以克服 ADP-核糖基化介导的耐药性。
Angew Chem Int Ed Engl. 2022 Nov 7;61(45):e202211498. doi: 10.1002/anie.202211498. Epub 2022 Oct 12.
3
Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue.
研发用于治疗肺部疾病的杀菌性口服药物组合。
ACS Infect Dis. 2025 Apr 11;11(4):929-939. doi: 10.1021/acsinfecdis.4c00948. Epub 2025 Apr 1.
4
A Simple In Vitro Method to Determine Bactericidal Activity Against Under Hypoxic Conditions.一种在缺氧条件下测定杀菌活性的简单体外方法。
Antibiotics (Basel). 2025 Mar 13;14(3):299. doi: 10.3390/antibiotics14030299.
5
A Physiologically Relevant In Vitro Model of Nonreplicating Persistent Mycobacterium tuberculosis in Caseum.一种在干酪中无复制持续性结核分枝杆菌的生理相关体外模型。
Curr Protoc. 2025 Mar;5(3):e70118. doi: 10.1002/cpz1.70118.
6
Durlobactam to boost the clinical utility of standard of care β-lactams against lung disease.杜洛巴坦可提高标准护理β-内酰胺类药物对肺部疾病的临床效用。
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0104624. doi: 10.1128/aac.01046-24. Epub 2024 Nov 20.
7
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of .由……的抗σ因子RshA功能丧失突变赋予的多药耐受性 。 你提供的原文似乎不完整,句末“of.”后面应该还有具体内容。
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0105124. doi: 10.1128/aac.01051-24. Epub 2024 Oct 29.
8
Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.用于鉴定非复制型结核分枝杆菌的分子和微生物学方法。
PLoS Pathog. 2024 Oct 9;20(10):e1012595. doi: 10.1371/journal.ppat.1012595. eCollection 2024 Oct.
9
Toward better cures for lung disease.寻求更好的肺部疾病治疗方法。
Clin Microbiol Rev. 2024 Dec 10;37(4):e0008023. doi: 10.1128/cmr.00080-23. Epub 2024 Oct 3.
非结核分枝杆菌肺病药物研发的挑战:结核来拯救。
J Exp Med. 2022 Jun 6;219(6). doi: 10.1084/jem.20220445. Epub 2022 May 11.
4
A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.用于研究非结核分枝杆菌肺病感染部位抗生素渗透的兔模型:大环内酯案例研究。
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0221221. doi: 10.1128/aac.02212-21. Epub 2022 Jan 31.
5
A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.结核分枝杆菌 NBTI DNA 拓扑异构酶抑制剂对脓肿分枝杆菌有效。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0151421. doi: 10.1128/AAC.01514-21. Epub 2021 Oct 4.
6
Treatment of Mycobacterium abscessus Pulmonary Disease.脓肿分枝杆菌肺病的治疗
Chest. 2022 Jan;161(1):64-75. doi: 10.1016/j.chest.2021.07.035. Epub 2021 Jul 24.
7
Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis.病变穿透和活动度限制了二线注射用药物在肺结核中的应用。
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0050621. doi: 10.1128/AAC.00506-21. Epub 2021 Jul 12.
8
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.阻断细菌萘氢醌氧化和 ADP-核糖基化可提高利福霉素类药物对脓肿分枝杆菌的活性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0097821. doi: 10.1128/AAC.00978-21.
9
Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus.哌啶-4-羧酰胺类化合物靶向分枝杆菌 DNA 回旋酶。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0067621. doi: 10.1128/AAC.00676-21.
10
A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity.一种具有广谱抗分枝杆菌活性的亮氨酰-tRNA合成酶抑制剂。
Antimicrob Agents Chemother. 2023 May 1;95(5). doi: 10.1128/AAC.02420-20. Epub 2021 Feb 8.